Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Direct and Indirect Costs of Inflammatory Bowel Disease: Ten Years of Follow Up in a Danish Population-Based Inception Cohort

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. The Sooner the Better? Cost-effectiveness of Early Biological Therapy in Patients With Crohn's Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Viewpoint: Inflammatory bowel diseases among immigrants from low- to high-incidence countries: opportunities and considerations

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Fibrogenesis and inflammation contribute to the pathogenesis of cirrhotic cardiomyopathy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The Sooner the Better? Cost-effectiveness of Early Biological Therapy in Patients With Crohn's Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cardiodynamic state is associated with systemic inflammation and fatal acute-on-chronic liver failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Inflammatory bowel disease [IBD], encompassing Crohn's disease [CD] and ulcerative colitis [UC], places a high burden on health care resources. To date, no study has assessed the combined direct and indirect cost of IBD in a population-based setting. Our aim was to assess this in a population-based inception cohort with 10 years of follow-up.

METHODS: All incident patients diagnosed with CD or UC, 2003-2004, in a well-defined area of Copenhagen, were followed prospectively until 2015. Direct and indirect costs were retrieved from Danish national registries. Data were compared with a control population [1:20]. Associations between the costs and multiple variables were assessed.

RESULTS: A total of 513 (CD: 213 [42%], UC: 300 [58%]) IBD patients were included. No significant differences were found in indirect costs between CD, UC, and the control population. Costs for CD patients were significantly higher than those for UC regarding all direct expenditures (except for5-aminosalicylates [5-ASA] and diagnostic expenses). Biologics accounted for €1.6 and €0.3 million for CD and UC, respectively. The total costs amounted to €42.6 million. Only patients with extensive colitis had significantly higher direct costs (proctitis: €2273 [1341-4092], left-sided: €3606 [2354-5311], extensive: €4093 [2313-6057], p <0.001). No variables were significantly associated with increased total costs in CD or in UC patients.

CONCLUSIONS: In this prospective population-based cohort, direct costs for IBD remain high. However, indirect costs did not surpass the control population. Total costs were mainly driven by hospitalisation, but indirect costs accounted for a higher percentage overall, although these did decrease over time.

PODCAST: This article has an associated podcast which can be accessed at https://academic.oup.com/ecco-jcc/pages/podcast.

Original languageEnglish
JournalJournal of Crohn's & colitis
Volume14
Issue number1
Pages (from-to)53-63
Number of pages11
ISSN1873-9946
DOIs
Publication statusPublished - 1 Jan 2020

ID: 57149758